PULMOCEF 250 (Cefuroxime Axetil USP 250mg) x 10 TABLETS.

Description: Pulmocef 250 is a broad-spectrum antibiotic containing Cefuroxime Axetil, designed to treat a variety of bacterial infections. This medication works by inhibiting the synthesis of the bacterial cell wall, leading to the death of the bacteria. It is effective against infections of the respiratory tract, urinary tract, skin, and soft tissues, as well as certain types of pneumonia.

3,900.00

Hurry Up! Sales Ends In:

Category:

Guaranteed Safe Checkout

PULMOCEF 250 (Cefuroxime Axetil USP 250mg) x 10 TABLETS.
Generic Name: Cefuroxime Axetil
Brand Name: Ceftin.
Class: Second-generation cephalosporin antibiotic.
Pack Size: 10 tablets.
Strength: 250 mg.
Amount: ₦3,900.

Description: Pulmocef 250 is a broad-spectrum antibiotic containing Cefuroxime Axetil, designed to treat a variety of bacterial infections. This medication works by inhibiting the synthesis of the bacterial cell wall, leading to the death of the bacteria. It is effective against infections of the respiratory tract, urinary tract, skin, and soft tissues, as well as certain types of pneumonia.

Key Features:
• Treats bacterial infections such as tonsillitis, sinusitis, otitis media, bronchitis, cystitis, pyelonephritis, and skin/soft tissue infections.
• Taken orally twice daily with food.
• Dosage may need to be adjusted for patients with kidney impairment.

Side Effects:
• Common side effects include diarrhoea, nausea, vomiting, and abdominal pain.
• Serious side effects may include allergic reactions, Clostridioides difficile-associated diarrhoea, and blood disorders.

Cautions:
• Not for use in patients with known allergy to cephalosporin antibiotics.
• May interact with certain medications like probenecid.
• Discontinue use if severe diarrhoea occurs and consult a doctor.
• Pregnancy and breastfeeding safety not fully established.

Reviews

There are no reviews yet.

Be the first to review “PULMOCEF 250 (Cefuroxime Axetil USP 250mg) x 10 TABLETS.”

Your email address will not be published. Required fields are marked *

Back To Top